Furthermore, MLN4924 treated AML cells show decreased binding ability between NF-κB and the miR-155 promoter and NF-κB-dependent transcriptional activity, and inhibit the PI3K/AKT pathway [171]. This evidence concerns the gene NFKB1 and acute myeloid leukemia.